View Filing Data

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2013	Jan. 12, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	0001069530
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		45,510,038
Entity Public Float			$ 82,913,105
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 48,588	$ 49,355
Marketable securities	1,250	6,899
Other current assets	265	253
Total current assets	50,103	56,507
Other assets		352
Total assets	50,103	56,859
Current liabilities:
Accounts payable	445	361
Accrued development expense	641	929
Deferred program fee revenue - current portion		7,832
Accrued compensation and benefits	712	853
Other current liabilities	3	24
Total current liabilities	1,801	9,999
Non-current liabilities:
Deferred program fee revenue - non-current portion		33,287
Deferred tax liabilities		437
Total liabilities	1,801	43,723
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 10,000,000 shares authorized, none issued and outstanding
Common stock, $.001 par value; 120,000,000 shares authorized; 45,510,038 and 45,326,940 shares issued and outstanding at December 31, 2013 and 2012, respectively	45	45
Additional paid-in-capital	152,363	148,738
Accumulated other comprehensive income	1	4
Accumulated deficit	(104,107)	(135,651)
Total stockholders' equity	48,302	13,136
Total liabilities and stockholders' equity	$ 50,103	$ 56,859

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2013	Dec. 31, 2012
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	45,510,038	45,326,940
Common stock, shares outstanding	45,510,038	45,326,940

Statements Of Operations - USD ($) shares in Thousands	12 Months Ended
Statements Of Operations - USD ($) shares in Thousands	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue:
Program fee revenue	$ 41,119,000	$ 10,641,000	$ 10,897,000
Collaboration revenue		249,000	587,000
Total revenue	41,119,000	10,890,000	11,484,000
Operating expenses:
Research and development	4,917,000	7,605,000	8,300,000
General and administrative	4,837,000	7,182,000	6,698,000
Total operating expenses	9,754,000	14,787,000	14,998,000
Operating income (loss)	31,365,000	(3,897,000)	(3,514,000)
Interest and other income, net	106,000	451,000	901,000
Income (loss) before provision for (benefit from) income taxes	31,471,000	(3,446,000)	(2,613,000)
Provision for (benefit from) income taxes	(73,000)	0	0
Net income (loss)	$ 31,544,000	$ (3,446,000)	$ (2,613,000)
Net income (loss) per share
Basic	$ 0.70	$ (0.08)	$ (0.06)
Diluted	$ 0.70	$ (0.08)	$ (0.06)
Weighted-average shares used in computing net income (loss) per share
Basic	45,007	44,753	44,160
Diluted	45,208	44,753	44,160

Statements Of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2010	$ 43	$ 161,957	$ 525	$ (129,592)	$ 32,933
Balance, Shares at Dec. 31, 2010	42,910,164
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards	$ 2	8,908			8,910
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards, shares	1,781,769
Issuance of common stock related to employee stock purchase plan		122			122
Issuance of common stock related to employee stock purchase plan, shares	40,084
Compensation with respect to non-employee option grants		60			60
Compensation with respect to employee option grants and share based awards		5,378			5,378
Other comprehensive loss			(397)		(397)
Net loss				(2,613)	(2,613)
Balance at Dec. 31, 2011	$ 45	176,425	128	(132,205)	44,393
Balance, Shares at Dec. 31, 2011	44,732,017
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards		(366)			(366)
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards, shares	574,370
Issuance of common stock related to employee stock purchase plan		64			64
Issuance of common stock related to employee stock purchase plan, shares	20,553
Compensation with respect to non-employee option grants		75			75
Compensation with respect to employee option grants and share based awards		6,535			6,535
Non-dividend cash distribution of $0.75 per share		(33,995)			(33,995)
Other comprehensive loss			(124)		(124)
Net loss				(3,446)	(3,446)
Balance at Dec. 31, 2012	$ 45	148,738	4	(135,651)	13,136
Balance, Shares at Dec. 31, 2012	45,326,940
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards		492			$ 492
Issuance of common stock pursuant to exercise of stock options and awards, net of taxes paid on net issuance of stock options and awards, shares	166,635				287,449
Issuance of common stock related to employee stock purchase plan		32			$ 32
Issuance of common stock related to employee stock purchase plan, shares	16,463
Compensation with respect to non-employee option grants		95			95
Compensation with respect to employee option grants and share based awards		3,006			3,006
Other comprehensive loss			(3)		(3)
Net loss				31,544	31,544
Balance at Dec. 31, 2013	$ 45	$ 152,363	$ 1	$ (104,107)	$ 48,302
Balance, Shares at Dec. 31, 2013	45,510,038

Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements Of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows used in operating activities:
Net income (loss)	$ 31,544	$ (3,446)	$ (2,613)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Deferred program fee revenue	(41,119)	(10,641)	(10,897)
Non-cash stock based compensation	3,101	6,610	5,428
Depreciation and amortization		122	163
Non-cash net interest income	(10)	342	1,141
Changes in operating assets and liabilities:
Receivables			7,114
Other current assets	(12)	105	(214)
Other non-current assets	352		74
Accounts payable	84	(103)	(643)
Accrued development expense	(288)	15	656
Accrued compensation and benefits	(141)	(62)	(797)
Excess tax benefits from equity-based compensation plans		(57)	339
Other accrued liabilities	(21)	(58)	(15)
Deferred tax liabilities	(437)	2	4
Net cash used in operating activities	(6,947)	(7,171)	(260)
Cash flows provided by investing activities:
Purchases of marketable securities	(6,644)	(20,768)	(2,497)
Maturities of marketable securities	12,300	38,390	62,400
Net cash provided by investing activities	5,656	17,622	59,903
Cash flows provided by (used in) financing activities:
Nondividend distribution		(33,995)
Excess tax benefits from equity-based compensation plans		57	(339)
Proceeds from issuance of common stock, net	524	(302)	9,042
Net cash provided by (used in) financing activities	524	(34,240)	8,703
Net increase (decrease) in cash and cash equivalents	(767)	(23,789)	68,346
Cash and cash equivalents at beginning of the period	49,355	73,144	4,798
Cash and cash equivalents at end of the period	$ 48,588	$ 49,355	$ 73,144

Summary Of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.

Revenue Recognition and Deferred Program Fee Revenue

Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

We and Pfizer have a strategic alliance to develop and commercialize REMOXY and up to three other opioid painkillers designed to reduce potential risks of unintended use. In connection with the strategic alliance, we recognize program fee revenue, collaboration revenue and milestone revenue. Program fee revenue is derived from upfront payments under the Pfizer Agreements, including the $150.0 million paid to us at the beginning of the strategic alliance and the $5.0 million we received in July 2010 in connection with an amendment the Pfizer Agreements. Through the end of the third quarter of 2013, these payments were recognized from receipt ratably over our estimate of the development period for the fourth of four drug candidates expected to be developed under the Pfizer Agreements. In October 2013, we and Pfizer amended the Pfizer Agreements to focus on REMOXY. As a result of the amendment, we no longer have any substantive responsibilities for development activities pursuant to the Pfizer Agreements and we recognized all remaining deferred program fee revenue as program fee revenue during the fourth quarter of 2013.

Collaboration revenues from reimbursement of development expenses are generally recognized when Pfizer has completed its review of the expenses invoiced to them.

We recognize milestone payments from Pfizer as revenue when we achieve the underlying developmental milestone as the milestone payments are not dependent upon any other future activities or achievement of any other future milestones and the achievement of each of the developmental milestones were substantively at risk and contingent at the effective date of the collaboration. Substantial effort is involved in achieving each of the developmental milestones. These milestones represent the culmination of discrete earnings processes and the amount of each milestone payment is reasonable in relation with the level of effort associated with the achievement of the milestone. Each milestone payment is non-refundable and non-creditable when made. The ongoing research and development services being provided to Pfizer under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration with Pfizer.

Cash, Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at two financial institutions and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not incurred material losses from our investments in these securities.

Marketable Securities and Fair Value Measurements

We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our available-for-sale securities in interest income in the accompanying statement of operations on a specific identification basis. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.

To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including the duration of time and the severity to which the fair value has been less than our amortized cost, any adverse changes in the investees’ financial condition and our intent to sell or whether it is more likely than not that we would be required to sell the marketable security before its anticipated recovery.

We measure our cash equivalents and marketable securities at fair value on a recurring basis and have significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements. We use significant observable inputs that include but are not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value.

Business Segments

We report segment information based on how we internally evaluate the operating performance of our business units, or segments. Our operations are confined to one business segment: the development of novel drugs.

Stock-based Compensation

We recognize non-cash expense in the statement of operations for the fair value of all share-based payments, including grants of employee stock options and other share based awards. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years.

We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance conditions. We estimate an implicit service period for achieving these performance conditions. Performance Awards vest and common stock is issued on achieving performance conditions. We recognize non-cash stock-based compensation expense for Performance Awards when we conclude that achieving a performance condition is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance conditions.

Net Loss per Share

Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and warrants. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands):



	Years ended December 31,
	2013		2012		2011
Numerator:
Net income (loss)	$	31,544	$	(3,446)	$	(2,613)
Denominator:
Weighted-average shares used to compute basic net income (loss) per share		45,007		44,753		44,160
Effect of dilutive securities - Dilution from employee stock plans		201		—		—
Weighted-average shares used to compute diluted net income (loss) per share		45,208		44,753	—	44,160
Net income (loss) per share - Basic	$	0.70	$	(0.08)	$	(0.06)
Net income (loss) per share - Diluted	$	0.70	$	(0.08)	$	(0.06)

We excluded weighted options outstanding to purchase common stock of 13.5 million for 2013, 13.2 million for 2012 and 13.7 million for 2011 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.

Income Taxes

We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these net deferred tax assets with a valuation allowance. We may in the future determine that more of our deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the quarter in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest and penalties recognized related to uncertain tax positions as interest expense.

Recent Accounting Pronouncements

We reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Cash And Cash Equivalents And Marketable Securities

12 Months Ended

Dec. 31, 2013

Cash And Cash Equivalents And Marketable Securities [Abstract]

Cash And Cash Equivalents And Marketable Securities

4. Cash and Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities held as available-for-sale consisted of the following (in thousands):



	Cash, Cash Equivalents and Marketable Securities
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
December 31, 2013
Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
Commercial paper		1,250		—		—		1,250		—		1,250
	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Reported as:
Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
Marketable securities		1,250		—		—		1,250		—		1,250
	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Maturities:
Matures in one year or less	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Matures one to three years		—		—		—		—		—		—
	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
December 31, 2012
Cash and cash equivalents	$	49,352	$	3	$	—	$	49,355	$	—	$	49,355
Corporate securities	$	6,898		1		—		6,899		—		6,899
	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254
Reported as:
Cash and cash equivalents	$	49,352	$	3	$	—	$	49,355	$	—	$	49,355
Marketable securities		6,898		1		—		6,899		—		6,899
	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254
Maturities:
Matures in one year or less	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254
Matures one to three years		—		—		—		—		—		—
	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254

To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. Our realized gains and losses on our marketable securities were immaterial in 2013, 2012 and 2011.

Our assets measured at fair value were (in thousands):



	Level 1		Level 2		Level 3		Total
December 31, 2013
Cash and money market fund	$	48,588	$	—	$	—	$	48,588
Commercial paper		—		1,250		—		1,250
	$	48,588	$	1,250	$	—	$	49,838
December 31, 2012
Cash and money market fund	$	1,817	$	—	$	—	$	1,817
Corporate securities		—		54,437		—		54,437
	$	1,817	$	54,437	$	—	$	56,254

Stockholders' Equity And Stock-Based Compensation

12 Months Ended

Dec. 31, 2013

Stockholders' Equity And Stock-Based Compensation [Abstract]

Stockholders' Equity And Stock-Based Compensation

6. Stockholders' Equity and Stock-Based Compensation

Preferred Stock

Our Board of Directors has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.

We have a stockholder rights plan, or the Rights Plan, designed to guard against partial tender offers and other coercive tactics to gain control of the Company without offering a fair and adequate price and terms to all of the Company’s stockholders. Pursuant to the Rights Plan, our Board of Directors declared and paid a dividend of one right to purchase one one-thousandth share of our Series A Participating Preferred Stock for each outstanding share of our common stock. Each of these rights entitles the registered holder to purchase from us one one-thousandth of a share of Series A Preferred at an exercise price of $40.00, subject to adjustment at any time. In 2013, we amended certain terms of the Rights Plan, primarily to provide for certain mechanical and procedural adjustments.

2008 Equity Incentive Plan

Under our 2008 Equity Incentive Plan, or 2008 Equity Plan, our employees, directors and consultants may receive share-based awards, including grants of stock options and Performance Awards. Our Board of Directors or a designated Committee of the Board is responsible for administration of the 2008 Equity Plan and determines the terms and conditions of each option granted, consistent with the terms of the plan.

Stock options generally expire ten years from the date of grant. Cancelled options become available for reissuance. Shares reserved for issuance and available for grant under the 2008 Equity Incentive Plan were 4.8 million as of December 31, 2013. The 2008 Equity Plan terminates in 2018.

The 2008 Equity Plan also provides for the automatic grant of options to purchase shares of common stock to outside directors. On the date of each annual stockholders’ meeting, each outside director is automatically granted an option to purchase 50,000 shares of common stock. The term of these options is ten years, the exercise price is 100% of the fair market value of the stock on the date of grant, and the option becomes exercisable as to 25% of the shares on the anniversary of its date of grant provided the optionee continues to serve as a director on such dates.

When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled and returned to the 2008 Equity Plan. We then use our cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.

Stock Options

The following summarizes information about stock option activity during 2013:



	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
				In years		In millions
Outstanding as of December 31, 2012	15,519,562	$	4.27	5.0	$	0.2
Granted	1,870,000	$	2.44
Exercised	(287,449)	$	3.98
Cancelled	(968,220)	$	4.25
Outstanding as of December 31, 2013	16,133,893	$	4.06	5.0	$	16.3
Vested and expected to vest at December 31, 2013	16,133,893	$	4.06	5.0	$	16.3
Exercisable at December 31, 2013	12,791,698	$	4.24	4.0	$	10.3

The pre-tax intrinsic value of options exercised, calculated by multiplying options exercised by the difference between our stock price on the date of exercise and the exercise price of the options, was approximately $0.2 million in 2013, immaterial in 2012 and $5.9 million in 2011.

The following summarizes information about stock options outstanding at December 31, 2013 by a range of exercise prices:



				Options outstanding				Options exercisable
					Weighted
					average	Weighted			Weighted
				Number of	remaining	average		Number of	average
Range of exercise prices				outstanding	contractual	exercise		vested	exercise
From		To		options	life (in years)	price		options	price
$	2.33	$	2.80	3,241,253	7.8	$	2.49	1,531,894	$	2.55
$	2.89	$	3.41	4,320,747	5.5	$	3.23	3,169,166	$	3.22
$	3.49	$	4.69	3,239,249	2.9	$	4.41	3,199,031	$	4.42
$	4.75	$	4.88	3,716,638	3.0	$	4.84	3,716,638	$	4.84
$	4.90	$	7.65	1,616,006	6.3	$	6.96	1,174,969	$	6.77
				16,133,893	5.0	$	4.06	12,791,698	$	4.24

We use Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of our common stock. For options granted to employees and directors, we used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 2013, 2012 and 2011, as follows:



	2013	2012	2011
Volatility	58% to 64%	56% to 64%	50% to 60%
Risk-free interest rates	1% to 2%	1%	1% to 3%
Expected life of option	7 years	6 years	6 years
Dividend yield	zero	zero	zero
Forfeiture rate	zero	7%	6%
Weighted average fair value of stock options granted	$1.54	$1.70	$4.68

Volatility is based on reviews of the historical volatility of our common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because we do not anticipate paying cash dividends in the foreseeable future. We estimate forfeitures and adjust this estimate periodically based in part on the extent to which actual forfeitures differ from our estimates.

For options granted to non-employees, we estimate the fair value of stock options granted using factors similar to those used for stock options granted to employees and directors and appropriate for the terms underlying the stock options granted to non-employees. We re-measure the compensation expense for options granted to non-employees each reporting period.

As of December 31, 2013, we expect to recognize compensation costs of $16.3 million related to non-vested options over the weighted average remaining recognition period of 2.5 years.

Performance Awards

At December 31, 2013, we have outstanding 3,250,065 shares of Performance Awards. We did not grant, issue via exercise or cancel any Performance Awards during 2013. If and when these Performance Awards vest, we would recognize $7.7 million in non-cash stock-based compensation. The modifications to outstanding Performance Awards in 2013 decreased the amount we would recognize if and when these Performance Awards vest by $3.5 million. These Performance Awards expire in 2022. If Performance Awards expire, the underlying shares return to the 2008 Equity Incentive Plan.

2000 Employee Stock Purchase Plan

Under the amended and restated 2000 Employee Stock Purchase Plan, or the Purchase Plan, eligible employees may purchase common stock through payroll deductions of up to 15% of the employee’s compensation. In May 2013, we issued 16,463 shares pursuant to the Purchase Plan.

The purchase price of the stock under the Purchase Plan is generally 85% of the lower of the fair market value of the common stock at the beginning of the offering period or at the end of the purchase period. We use Black-Scholes to estimate the fair value of rights granted under the Purchase Plan, using assumptions similar to those used in determining the fair value of options. Stock based compensation costs related to the Purchase Plan was immaterial in 2013.

Stock-Based Compensation

Our non-cash stock-based compensation was $3.1 million in 2013, $6.6 million in 2012 and $5.4 million in 2011. In 2013, we modified outstanding share-based awards to provide for full acceleration of vesting in the event that a plan participant has their service provider status with the Company terminated by the Company (or any successor entity) without cause or terminated by such participant for good reason at any time following a change in control of the Company. As a result of these modifications, the amount of stock-based compensation we recognized in 2013 was reduced by an immaterial amount.

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Income Taxes

8. Income Taxes

We recorded a non-cash benefit from income taxes in 2013 related to previously unrecognized tax benefits for use of certain research and development tax credits in 2006. Other than this benefit, we did not provide for income taxes in 2013 as a result of we had a net operating loss for tax purposes in 2013. A reconciliation between the amount computed by multiplying our income before benefit from income taxes for 2013 by the U.S. statutory tax rate and our benefit from income taxes follows (in thousands):



	2013
Tax at U.S. statutory tax rate of 34%	$	10,725
State taxes		(73)
Equity-based compensation		844
Research credits		(81)
Other		(242)
Change in valuation allowance		(11,246)
Benefit from income taxes	$	(73)

We did not have a provision for income taxes in 2012 or 2011 because we had a net operating loss for tax purposes in those years.

Deferred tax assets and valuation allowance

Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets are as follows (in thousands):



	December 31,
	2013		2012		2011
Deferred tax assets:
Net operating loss carryforwards	$	10,200	$	9,200	$	6,500
Stock-related compensation		11,100		11,700		12,000
Research & development credit carryforwards		5,700		6,400		6,300
Deferred license fee revenue		—		14,600		19,900
Other		600		600		900
		27,600		42,500		45,600
Valuation allowance		(27,600)		(42,200)		(45,300)
	$	—	$	300	$	300

We are uncertain about the timing and amount of any future profits. Accordingly, we offset our deferred tax assets by a valuation allowance. The valuation allowance decreased by $15.0 in 2013, $3.1 million in 2012 and $0.8 million in 2011.

Our pre-tax net operating loss carryforwards of $32.7 million are federal and expire between 2029 and 2033. Our deferred tax assets exclude certain federal tax deductions associated with stock option transactions over and above the stock related compensation expenses in our financial statements by approximately $2.6 million. If and when we are able to reduce our income taxes payable with these tax deductions, we will credit additional paid-in capital.

As of December 31, 2013, we had federal research and development tax credits of approximately $9.5 million, which expire in the years 2023 through 2033.

Our deferred tax liabilities at December 31, 2012 resulted from reserves for credits used to reduce state taxes paid for 2006 and 2008. In 2013, we concluded that these reserves will never be realized. Interest expense related to our tax positions was immaterial for 2013, 2012 and 2011.

Unrecognized tax benefits

We have unrecognized tax benefits related primarily to tax credits. In 2013, we reduced our unrecognized tax benefits for the lapse of applicable statute of limitations for tax credits used in prior years. A reconciliation of the beginning and ending unrecognized tax benefits recorded for 2013, 2012 and 2011 follows (in thousands):



		2013		2012		2011
Beginning balance	$	5,200	$	5,100	$	4,800
Additions based on tax positions related to the current year		100		100		300
Lapse of applicable statute of limitations		(600)		—		—
Reductions for tax positions related to prior years		(900)		—		—
Ending balance	$	3,800	$	5,200	$	5,100

Selected Quarterly Financial Data

12 Months Ended

Dec. 31, 2013

Selected Quarterly Financial Data [Abstract]

Selected Quarterly Financial Data

11. Selected Quarterly Financial Data (Unaudited) (in thousands, except per share data)



	Quarters Ended
	March 31		June 30		September 30		December 31
2013
Total revenue	$	1,958	$	1,959	$	1,958	$	35,244
Net income (loss)	$	(408)	$	(301)	$	(762)	$	33,015
Basic net income (loss) per share	$	(0.01)	$	(0.01)	$	(0.02)	$	0.73
Diluted net income (loss) per share	$	(0.01)	$	(0.01)	$	(0.02)	$	0.72
2012
Total revenue	$	2,973	$	2,724	$	2,725	$	2,468
Net income (loss)	$	30	$	(130)	$	(1,550)	$	(1,796)
Basic and diluted net income (loss) per share	$	0.00	$	(0.00)	$	(0.03)	$	(0.04)

Summary Of Significant Accounting Policies (Policy)

12 Months Ended

Dec. 31, 2013

Summary Of Significant Accounting Policies [Abstract]

Use Of Estimates

Use of Estimates

Revenue Recognition And Deferred Program Fee Revenue

Revenue Recognition and Deferred Program Fee Revenue

Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collection is reasonably assured.

Collaboration revenues from reimbursement of development expenses are generally recognized when Pfizer has completed its review of the expenses invoiced to them.

Cash, Cash Equivalents And Concentration Of Credit Risk

Cash, Cash Equivalents and Concentration of Credit Risk

Marketable Securities And Fair Value Measurements

Marketable Securities and Fair Value Measurements

Business Segments

Stock-Based Compensation

Stock-based Compensation

Net Loss Per Share

Net Loss per Share



	Years ended December 31,
	2013		2012		2011
Numerator:
Net income (loss)	$	31,544	$	(3,446)	$	(2,613)
Denominator:
Weighted-average shares used to compute basic net income (loss) per share		45,007		44,753		44,160
Effect of dilutive securities - Dilution from employee stock plans		201		—		—
Weighted-average shares used to compute diluted net income (loss) per share		45,208		44,753	—	44,160
Net income (loss) per share - Basic	$	0.70	$	(0.08)	$	(0.06)
Net income (loss) per share - Diluted	$	0.70	$	(0.08)	$	(0.06)

Income Taxes

Recent Accounting Pronouncements

Cash And Cash Equivalents And Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2013

Cash And Cash Equivalents And Marketable Securities [Abstract]

Cash, Cash Equivalents And Marketable Securities



	Cash, Cash Equivalents and Marketable Securities
	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
December 31, 2013
Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
Commercial paper		1,250		—		—		1,250		—		1,250
	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Reported as:
Cash and cash equivalents	$	48,587	$	1	$	—	$	48,588	$	—	$	48,588
Marketable securities		1,250		—		—		1,250		—		1,250
	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Maturities:
Matures in one year or less	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
Matures one to three years		—		—		—		—		—		—
	$	49,837	$	1	$	—	$	49,838	$	—	$	49,838
December 31, 2012
Cash and cash equivalents	$	49,352	$	3	$	—	$	49,355	$	—	$	49,355
Corporate securities	$	6,898		1		—		6,899		—		6,899
	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254
Reported as:
Cash and cash equivalents	$	49,352	$	3	$	—	$	49,355	$	—	$	49,355
Marketable securities		6,898		1		—		6,899		—		6,899
	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254
Maturities:
Matures in one year or less	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254
Matures one to three years		—		—		—		—		—		—
	$	56,250	$	4	$	—	$	56,254	$	—	$	56,254

Assets Measured At Fair Value On Recurring Basis



	Level 1		Level 2		Level 3		Total
December 31, 2013
Cash and money market fund	$	48,588	$	—	$	—	$	48,588
Commercial paper		—		1,250		—		1,250
	$	48,588	$	1,250	$	—	$	49,838
December 31, 2012
Cash and money market fund	$	1,817	$	—	$	—	$	1,817
Corporate securities		—		54,437		—		54,437
	$	1,817	$	54,437	$	—	$	56,254

Stockholders' Equity And Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2013

Stockholders' Equity And Stock-Based Compensation [Abstract]

Stock Option Activity



	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
				In years		In millions
Outstanding as of December 31, 2012	15,519,562	$	4.27	5.0	$	0.2
Granted	1,870,000	$	2.44
Exercised	(287,449)	$	3.98
Cancelled	(968,220)	$	4.25
Outstanding as of December 31, 2013	16,133,893	$	4.06	5.0	$	16.3
Vested and expected to vest at December 31, 2013	16,133,893	$	4.06	5.0	$	16.3
Exercisable at December 31, 2013	12,791,698	$	4.24	4.0	$	10.3

Information About Stock Options Outstanding



				Options outstanding				Options exercisable
					Weighted
					average	Weighted			Weighted
				Number of	remaining	average		Number of	average
Range of exercise prices				outstanding	contractual	exercise		vested	exercise
From		To		options	life (in years)	price		options	price
$	2.33	$	2.80	3,241,253	7.8	$	2.49	1,531,894	$	2.55
$	2.89	$	3.41	4,320,747	5.5	$	3.23	3,169,166	$	3.22
$	3.49	$	4.69	3,239,249	2.9	$	4.41	3,199,031	$	4.42
$	4.75	$	4.88	3,716,638	3.0	$	4.84	3,716,638	$	4.84
$	4.90	$	7.65	1,616,006	6.3	$	6.96	1,174,969	$	6.77
				16,133,893	5.0	$	4.06	12,791,698	$	4.24

Weighted Average Fair Value Of Options Granted



	2013	2012	2011
Volatility	58% to 64%	56% to 64%	50% to 60%
Risk-free interest rates	1% to 2%	1%	1% to 3%
Expected life of option	7 years	6 years	6 years
Dividend yield	zero	zero	zero
Forfeiture rate	zero	7%	6%
Weighted average fair value of stock options granted	$1.54	$1.70	$4.68

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Schedule Of Effective Income Tax Rate Reconciliation



	2013
Tax at U.S. statutory tax rate of 34%	$	10,725
State taxes		(73)
Equity-based compensation		844
Research credits		(81)
Other		(242)
Change in valuation allowance		(11,246)
Benefit from income taxes	$	(73)

Schedule Of Deferred Tax Assets And Valuation Allowance



	December 31,
	2013		2012		2011
Deferred tax assets:
Net operating loss carryforwards	$	10,200	$	9,200	$	6,500
Stock-related compensation		11,100		11,700		12,000
Research & development credit carryforwards		5,700		6,400		6,300
Deferred license fee revenue		—		14,600		19,900
Other		600		600		900
		27,600		42,500		45,600
Valuation allowance		(27,600)		(42,200)		(45,300)
	$	—	$	300	$	300

Schedule Of Unrecognized Tax Benefits



		2013		2012		2011
Beginning balance	$	5,200	$	5,100	$	4,800
Additions based on tax positions related to the current year		100		100		300
Lapse of applicable statute of limitations		(600)		—		—
Reductions for tax positions related to prior years		(900)		—		—
Ending balance	$	3,800	$	5,200	$	5,100

Selected Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2013

Selected Quarterly Financial Data [Abstract]

Quarterly Financial Information



	Quarters Ended
	March 31		June 30		September 30		December 31
2013
Total revenue	$	1,958	$	1,959	$	1,958	$	35,244
Net income (loss)	$	(408)	$	(301)	$	(762)	$	33,015
Basic net income (loss) per share	$	(0.01)	$	(0.01)	$	(0.02)	$	0.73
Diluted net income (loss) per share	$	(0.01)	$	(0.01)	$	(0.02)	$	0.72
2012
Total revenue	$	2,973	$	2,724	$	2,725	$	2,468
Net income (loss)	$	30	$	(130)	$	(1,550)	$	(1,796)
Basic and diluted net income (loss) per share	$	0.00	$	(0.00)	$	(0.03)	$	(0.04)

Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator
Net income (loss)					$ 31,544	$ (3,446)	$ (2,613)
Denominator
Weighted-average shares used to compute basic net income (loss) per share					45,007	44,753	44,160
Effect of dilutive securities - Dilution from employee stock plans					201
Weighted-average shares used to compute diluted net income (loss) per share					45,208	44,753	44,160
Net income (loss) per share - Basic	$ 0.73	$ (0.02)	$ (0.01)	$ (0.01)	$ 0.70	$ (0.08)	$ (0.06)
Net income (loss) per share - Diluted	$ 0.72	$ (0.02)	$ (0.01)	$ (0.01)	$ 0.70	$ (0.08)	$ (0.06)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Cash And Cash Equivalents And Marketable Securities (Cash, Cash Equivalents And Marketable Securities) (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 48,588	$ 49,355	$ 73,144	$ 4,798
Cash and cash equivalents, Short Term Investment, Amortized Cost	49,837	56,250
Cash and cash equivalents, Short Term Investment Unrealized Gains	1	4
Cash and cash equivalents, Short Term Investment Unrealized Loss
Accrued Interest
Estimated Fair Value, Marketable securities	1,250	6,899
Cash and cash equivalents, Short Term Investment, Fair Value	49,838	56,254
Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, Amortized Cost Basis	1,250	6,898
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	1,250	6,899
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	48,587	49,352
Available-for-sale securities, Gross Unrealized Gains	1	3
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	48,588	49,355
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, Amortized Cost Basis	1,250
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	1,250
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, Amortized Cost Basis		6,898
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities		6,899
Cash And Cash Equivalents, Reported Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	48,587	49,352
Available-for-sale securities, Gross Unrealized Gains	1	3
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	48,588	49,355
Matures In One Year Or Less [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost	49,837	56,250
Available-for-sale securities, Gross Unrealized Gains	1	4
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Short Term Investment, Fair Value	49,838	56,254
Matures One To Three Years [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	49,838	56,254
Estimated Fair Value, Fair Value Disclosure [Member] \| Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated Fair Value, Marketable securities	1,250	6,899
Estimated Fair Value, Fair Value Disclosure [Member] \| Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Fair Value	48,588	49,355
Estimated Fair Value, Fair Value Disclosure [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated Fair Value, Marketable securities	1,250
Estimated Fair Value, Fair Value Disclosure [Member] \| Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated Fair Value, Marketable securities		6,899
Estimated Fair Value, Fair Value Disclosure [Member] \| Cash And Cash Equivalents, Reported Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Fair Value	48,588	49,355
Estimated Fair Value, Fair Value Disclosure [Member] \| Matures In One Year Or Less [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	$ 49,838	$ 56,254

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-cash stock based compensation	$ 3,101	$ 6,610	$ 5,428
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	4,800,000
Common stock shares granted to outside directors	50,000
Expiration period of stock options granted	10 years
Fair market value percent	100.00%
Options exercisable percentage	25.00%
Pre-tax intrinsic value of options exercised	$ 200		$ 5,900
Compensation costs prior to forfeiture	$ 16,300
Weighted average remaining recognition period	2 years 6 months
2000 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair market value percent	85.00%
Payroll deductions	15.00%
Shares reserved for issuance	16,463
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards granted	3,250,065
Additional stock compensation expense	$ 7,700
Decrease to additional stock compensation expense	$ 3,500
Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, Preferred Stock	$ 40.00

Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity And Stock-Based Compensation [Abstract]
Beginning Balance, Number of Options, Outstanding	15,519,562
Number of Options, Granted	1,870,000
Number of Options, Exercised	(287,449)
Number of Options, Cancelled	(968,220)
Ending Balance, Number of Options, Outstanding	16,133,893	15,519,562
Number of Options, Vested and expected to vest	16,133,893
Number of Options, Exercisable	12,791,698
Beginning Balance, Weighted Average Exercise Price	$ 4.27
Weighted Average Exercise Price, Granted	2.44
Weighted Average Exercise Price, Exercised	3.98
Weighted Average Exercise Price, Cancelled	4.25
Ending Balance, Weighted Average Exercise Price	4.06	$ 4.27
Weighted Average Exercise Price, Vested and expected to vest	4.06
Weighted Average Exercise Price, Exercisable	$ 4.24
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	5 years	5 years
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	5 years	5 years
Weighted Average Remaining Contractual Term, Vested and expected to vest	5 years
Weighted Average Remaining Contractual Term, Exercisable	4 years
Beginning Balance, Aggregate Intrinsic Value	$ 0.2
Ending Balance, Aggregate Intrinsic Value	16.3	$ 0.2
Aggregate Intrinsic Value, Vested and expected to vest	16.3
Aggregate Intrinsic Value, Exercisable	$ 10.3

Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)	12 Months Ended
	Dec. 31, 2013 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, outstanding \| shares	16,133,893
Weighted average remaining contractual life	5 years
Weighted average exercise price, Options outstanding	$ 4.06
Number of vested options, Options exercisable \| shares	12,791,698
Weighted average exercise price, Options exercisable	$ 4.24
$2.33 - $2.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	2.33
Range of exercise prices, Maximum	$ 2.80
Stock options, outstanding \| shares	3,241,253
Weighted average remaining contractual life	7 years 9 months 18 days
Weighted average exercise price, Options outstanding	$ 2.49
Number of vested options, Options exercisable \| shares	1,531,894
Weighted average exercise price, Options exercisable	$ 2.55
$2.89 - $3.41 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	2.89
Range of exercise prices, Maximum	$ 3.41
Stock options, outstanding \| shares	4,320,747
Weighted average remaining contractual life	5 years 6 months
Weighted average exercise price, Options outstanding	$ 3.23
Number of vested options, Options exercisable \| shares	3,169,166
Weighted average exercise price, Options exercisable	$ 3.22
$3.49 - $4.69 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	3.49
Range of exercise prices, Maximum	$ 4.69
Stock options, outstanding \| shares	3,239,249
Weighted average remaining contractual life	2 years 10 months 24 days
Weighted average exercise price, Options outstanding	$ 4.41
Number of vested options, Options exercisable \| shares	3,199,031
Weighted average exercise price, Options exercisable	$ 4.42
$4.75 - $4.88 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	4.75
Range of exercise prices, Maximum	$ 4.88
Stock options, outstanding \| shares	3,716,638
Weighted average remaining contractual life	3 years
Weighted average exercise price, Options outstanding	$ 4.84
Number of vested options, Options exercisable \| shares	3,716,638
Weighted average exercise price, Options exercisable	$ 4.84
$4.90 - $7.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	4.90
Range of exercise prices, Maximum	$ 7.65
Stock options, outstanding \| shares	1,616,006
Weighted average remaining contractual life	6 years 3 months 18 days
Weighted average exercise price, Options outstanding	$ 6.96
Number of vested options, Options exercisable \| shares	1,174,969
Weighted average exercise price, Options exercisable	$ 6.77

Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders' Equity And Stock-Based Compensation [Abstract]
Volatility, Minimum	58.00%	56.00%	50.00%
Volatility, Maximum	64.00%	64.00%	60.00%
Risk-free interest rates		1.00%
Risk-free interest rates, Minimum	1.00%		1.00%
Risk-free interest rates, Maximum	2.00%		3.00%
Expected life of option	7 years	6 years	6 years
Dividend yield	0.00%	0.00%	0.00%
Forfeiture rate	0.00%	7.00%	6.00%
Weighted average fair value of stock options granted	$ 1.54	$ 1.70	$ 4.68

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ (73,000)	$ 0	$ 0
Valuation allowance decreased	15,000,000	$ 3,100,000	$ 800,000
Part of valuation allowance as tax benefits associated with stock option transactions	2,600,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Pre-tax net operating loss carryforwards	32,700,000
Federal research and development tax credits	$ 9,500,000
Federal [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	Jan. 01, 2029
Expiration date of federal research and development tax credits	Jan. 01, 2023
Federal [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	Dec. 31, 2033
Expiration date of federal research and development tax credits	Dec. 31, 2033

Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]
Tax at U.S. statutory tax rate of 34%	$ 10,725,000
State taxes	(73,000)
Equity-based compensation	844,000
Research credits	(81,000)
Other	(242,000)
Change in valuation allowance	(11,246,000)
Benefit from income taxes	$ (73,000)	$ 0	$ 0
U.S. statutory tax rate	34.00%

Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes [Abstract]
Net operating loss carryforwards	$ 10,200	$ 9,200	$ 6,500
Stock-related compensation	11,100	11,700	12,000
Research & development credit carryforwards	5,700	6,400	6,300
Deferred license fee revenue		14,600	19,900
Other	600	600	900
Total deferred tax assets	27,600	42,500	45,600
Valuation allowance	$ (27,600)	(42,200)	(45,300)
Net deferred tax assets		$ 300	$ 300

Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Selected Quarterly Financial Data [Abstract]
Total revenue	$ 35,244	$ 1,958	$ 1,959	$ 1,958	$ 2,468	$ 2,725	$ 2,724	$ 2,973	$ 41,119	$ 10,890	$ 11,484
Net income (loss)	$ 33,015	$ (762)	$ (301)	$ (408)	$ (1,796)	$ (1,550)	$ (130)	$ 30	$ 31,471	$ (3,446)	$ (2,613)
Net income (loss) per share - Basic	$ 0.73	$ (0.02)	$ (0.01)	$ (0.01)					$ 0.70	$ (0.08)	$ (0.06)
Net income (loss) per share - Diluted	$ 0.72	$ (0.02)	$ (0.01)	$ (0.01)					$ 0.70	$ (0.08)	$ (0.06)
Basic and diluted net income (loss) per share					$ (0.04)	$ (0.03)	$ 0.00	$ 0.00

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

Statements Of Stockholders' Equity (Parenthetical)	12 Months Ended
Statements Of Stockholders' Equity (Parenthetical)	Dec. 31, 2012 $ / shares
Statements Of Stockholders' Equity [Abstract]
Non-dividend cash distribution, per share	$ 0.75

General	12 Months Ended
General	Dec. 31, 2013
General [Abstract]
General	1. General We are a biopharmaceutical company that develops novel drugs. Our lead drug candidate is called REMOXY® (oxycodone) Extended-Release Capsules CII. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. REMOXY and three other abuse-resistant painkillers are being developed pursuant to the collaboration agreement and license agreement, or the Pfizer Agreements, between us and King Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc., or Pfizer. In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all.

Collaboration Agreements	12 Months Ended
Collaboration Agreements	Dec. 31, 2013
Collaboration Agreements [Abstract]
Collaboration Agreements	3. Collaboration Agreements Pfizer, Inc. Our strategic alliance with Pfizer, as amended, includes a collaboration agreement and a license agreement to develop and commercialize REMOXY. We received a $150.0 million upfront fee in connection with the closing of this strategic alliance and $5.0 million in July 2010 in connection with an amendment to this strategic alliance. As of December 31, 2013, all of these payments had been recognized as program fee revenue, including $41.1 million in 2013, $10.6 million in 2012 and $10.9 million in 2011. In addition, Pfizer has funded development expenses incurred by us pursuant to the collaboration agreement, of which we recorded as collaboration revenue $0.2 million in 2012 and $0.6 million in 2011. Pfizer is obligated to fund the commercialization expenses of, and has the exclusive right to market and sell, REMOXY. The royalty rate for net sales of REMOXY in the United States is 20%, except as to the first $1.0 billion in cumulative net sales in the United States, for which the royalty is set at 15%. The royalty rate for net sales of REMOXY outside the United States is 10% on net sales. Durect Corporation We have an exclusive, worldwide licensing agreement with Durect Corporation to use a patented technology that forms the basis for certain drug candidates, including REMOXY. We have sub-licensed to Pfizer certain rights to develop and to commercialize REMOXY. Under the agreement with Durect, we control all of the preclinical, clinical, commercial manufacturing and sales/marketing activities for REMOXY and other abuse-resistant opioid painkillers. We reimburse Durect for formulation and related work, and will make milestone payments based on the achievement of certain technical, clinical or regulatory milestones. We also are responsible to pay Durect royalties on any related drug sales. Pfizer is obligated to reimburse us for costs we incur under the agreement with Durect for REMOXY, including royalties.

Property And Equipment	12 Months Ended
Property And Equipment	Dec. 31, 2013
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment Property and equipment at December 31, 2013 and 2012 consisted of furniture and equipment with a purchase value of $0.6 million. All of our property and equipment was fully depreciated prior to December 31, 2012. Depreciation and amortization expense was $0.1 million in 2012 and $0.2 million in 2011.

Employee 401(k) Benefit Plan	12 Months Ended
Employee 401(k) Benefit Plan	Dec. 31, 2013
Employee 401(k) Benefit Plan [Abstract]
Employee 401(k) Benefit Plan	7. Employee 401(k) Benefit Plan We have a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits us to make additional matching contributions on behalf of all employees. Through December 31, 2013, we have not made any matching contributions.

Legal Proceedings	12 Months Ended
Legal Proceedings	Dec. 31, 2013
Legal Proceedings [Abstract]
Legal Proceedings	10. Legal proceedings K B Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy. On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas. This complaint alleges, among other things, violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act arising out of allegedly untrue or misleading statements of material facts made by us regarding REMOXY’s development and regulatory status during the purported class period, February 3, 2011 through June 23, 2011. The complaint states that monetary damages are being sought, but no amounts are specified. On June 3, 2013, the Court certified a class consisting of all purchasers of our common stock and a class period of December 27, 2010 through June 26, 2011.

Summary Of Significant Accounting Policies (Narrative) (Details) shares in Millions, $ in Millions	1 Months Ended	12 Months Ended			85 Months Ended
	Jul. 31, 2010 USD ($)	Dec. 31, 2013 segment item shares	Dec. 31, 2012 shares	Dec. 31, 2011 shares	Nov. 30, 2012 USD ($)
Summary Of Significant Accounting Policies [Abstract]
Upfront cash payment \| $	$ 5.0				$ 150.0
Number of financial institutions that maintain cash and cash equivalents		2
Contractual maturity of a particular investment		1 year
Number of financial institutions that maintain marketable securities		1
Number of business segments \| segment		1
Vesting period of stock options		4 years
Anti-dilutive shares excluded from computation of diluted net loss per share \| shares		13.5	13.2	13.7

Collaboration Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended			85 Months Ended
Collaboration Agreements (Details) - USD ($) $ in Thousands	Jul. 31, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2012
Collaboration Agreements [Abstract]
Upfront cash payment	$ 5,000				$ 150,000
Program fee revenue		$ 41,119	$ 10,641	$ 10,897
Collaboration revenue			$ 249	$ 587
Royalty rate for net sales		20.00%
Cumulative net sales		$ 1,000,000
Royalty rate for cumulative net sales		15.00%
Royalty rate on all of net sales		10.00%

Cash And Cash Equivalents And Marketable Securities (Assets Measured At Fair Value On Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 49,838	$ 56,254
Cash And Money Market Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	48,588	1,817
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	1,250
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		54,437
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	48,588	1,817
Level 1 [Member] \| Cash And Money Market Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	48,588	1,817
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	1,250	54,437
Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	1,250
Level 2 [Member] \| Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		54,437
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Cash And Money Market Fund [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] \| Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Property And Equipment (Details) - USD ($) $ in Millions	12 Months Ended
Property And Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 0.1	$ 0.2
Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, purchase value	$ 0.6		$ 0.6

Leases And Commitments (Narrative) (Details) $ in Millions	12 Months Ended
Leases And Commitments (Narrative) (Details) $ in Millions	Dec. 31, 2013 USD ($) ft²	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)
Office space \| ft²	6,000
Rent expense \| $	$ 0.1	$ 0.1	$ 0.6
Austin, TX [Member]
Operating lease expiration year	2014